FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4385655279> ?p ?o ?g. }

• W4385655279 endingPage "e762168f" @default.
• W4385655279 startingPage "e762168f" @default.
• W4385655279 abstract "Topic: 14. Myeloma and other monoclonal gammopathies - Clinical Background: Multiple Myeloma (MM) is a heterogenous disease characterized by subsequent relapses. The disease becomes more aggressive after each relapse with shorter time between relapses, meaning less duration of response per late line of treatment and consequently, treatment refractoriness. There is increasing evidence to support a treatment paradigm shift from the traditional fixed duration strategy to a continuous therapy approach to improve outcomes in accordance with socio-demographic and clinical patient’s characteristics. The determinants of treatment duration (DoT) and its relationship with survival in real-life practice have been little investigated, including reasons for treatment discontinuation. Aims: To investigate the relationship between DoT and outcomes in clinical practice, analyzing treatment received per line, as fixed duration or continuous therapy, factors that may have an influence in treatment continuation and patients satisfaction with treatment prescribed. Methods: DOrianT is an observational, prospective, non-interventional, multicentric study, involving 14 hospitals in Spain, which enrolled MM, amyloidosis AL and patients with more than one gammopathy to assess the DoT and response in routine clinical practice. At study entry patients were receiving active treatment under a fix-duration or continuous strategy. An interim descriptive analysis has been conducted once 50% of patients have completed the defined 12 months follow up period. The reported information is based on the 207 MM patients enrolled. Results: At study entry and current treatment initiation, median age was 73 (9.73) years, 103 (49.8%) patients were male and 104 (50.2%) female. 49 (23.9%) and 156 (76.1%) lived in rural and urban areas. 17 (8.9%) lived alone, 166 (86.5%) with a family member and 9 (4.7%) lived alone with help of a caregiver. 153 (78.9%) were independent, 25 (12.9%) dependent grade I, 12 (6.2%) grade II and 4 (2.1%) grade III. The majority of patients were retired 155 (78.3%) and 14 (7.1%) were in active employment. 100 (48.3%) patients completed the follow up period, with a median follow up of 11.57 (6.08, 12.19) months. 10 (9.3%) patients abandoned the study prematurely. 107 (51.7%) patients were at 1L of treatment, 59 (28.5%) at 2L, 28 (13.5%) at 3L and 13 (6.3%) at subsequent lines. 38 patients were at maintenance/consolidation setting, 29 (76.3%) at 1L and 9 (23.7%) at 2L. 71 (34.3%) patients received previous SCT, 59 (83.1%) at 1L, 11 (15.5%) at 2L and 1 (1.4%) at 3L. 98 (48.0%) patients were performed a cytogenetic test at treatment initiation, 42 (42.9%) reported high risk and 56 (57.1%) standard risk. ECOG was performed in 96 (47.1%) patients and IMWG Frailty Status was available in 18 (8.8%). Treatment satisfaction questionnaire for medication (TSQM) was performed in 190 (92.7%) patients, 71.9 (15.5) reported convenience with current treatment. Prescribed regimens per line and main agent are listed in table 1. 42 (20.5%) patients received a fixed duration vs 163 (79.5%) continuous treatment strategy. Summary/Conclusion: Based on this preliminary analysis, the majority of MM patients are under a continuous treatment strategy, in early treatment lines and following a treatment based on monoclonal antibodies as main agent. The majority presented concomitant diseases at study entry. ECOG and frailty status are not widely used at routine clinical practice once the treatment is prescribed. Further analysis will be conducted to analyze DoT and its influence with treatment prescribed and patient’s satisfaction.Keywords: Multiple myeloma, Treatment, Monoclonal gammopathy, Real world data" @default.
• W4385655279 created "2023-08-09" @default.
• W4385655279 creator A5020990345 @default.
• W4385655279 creator A5021328479 @default.
• W4385655279 creator A5027047109 @default.
• W4385655279 creator A5036725271 @default.
• W4385655279 creator A5053335237 @default.
• W4385655279 creator A5068349233 @default.
• W4385655279 creator A5084674705 @default.
• W4385655279 date "2023-08-01" @default.
• W4385655279 modified "2023-09-27" @default.
• W4385655279 title "PB2137: SOCIO-DEMOGRAPHIC FEATURES AND TREATMENT PATTERNS OF MULTIPLE MYELOMA PATIENTS IN SPAIN: AN INTERIM ANALYSIS OF DORIANT STUDY" @default.
• W4385655279 doi "https://doi.org/10.1097/01.hs9.0000975312.76216.8f" @default.
• W4385655279 hasPublicationYear "2023" @default.
• W4385655279 type Work @default.
• W4385655279 citedByCount "0" @default.
• W4385655279 crossrefType "journal-article" @default.
• W4385655279 hasAuthorship W4385655279A5020990345 @default.
• W4385655279 hasAuthorship W4385655279A5021328479 @default.
• W4385655279 hasAuthorship W4385655279A5027047109 @default.
• W4385655279 hasAuthorship W4385655279A5036725271 @default.
• W4385655279 hasAuthorship W4385655279A5053335237 @default.
• W4385655279 hasAuthorship W4385655279A5068349233 @default.
• W4385655279 hasAuthorship W4385655279A5084674705 @default.
• W4385655279 hasBestOaLocation W43856552791 @default.
• W4385655279 hasConcept C126322002 @default.
• W4385655279 hasConcept C1862650 @default.
• W4385655279 hasConcept C187212893 @default.
• W4385655279 hasConcept C23131810 @default.
• W4385655279 hasConcept C2776364478 @default.
• W4385655279 hasConcept C2778715236 @default.
• W4385655279 hasConcept C2779974597 @default.
• W4385655279 hasConcept C535046627 @default.
• W4385655279 hasConcept C61943457 @default.
• W4385655279 hasConcept C71924100 @default.
• W4385655279 hasConceptScore W4385655279C126322002 @default.
• W4385655279 hasConceptScore W4385655279C1862650 @default.
• W4385655279 hasConceptScore W4385655279C187212893 @default.
• W4385655279 hasConceptScore W4385655279C23131810 @default.
• W4385655279 hasConceptScore W4385655279C2776364478 @default.
• W4385655279 hasConceptScore W4385655279C2778715236 @default.
• W4385655279 hasConceptScore W4385655279C2779974597 @default.
• W4385655279 hasConceptScore W4385655279C535046627 @default.
• W4385655279 hasConceptScore W4385655279C61943457 @default.
• W4385655279 hasConceptScore W4385655279C71924100 @default.
• W4385655279 hasIssue "S3" @default.
• W4385655279 hasLocation W43856552791 @default.
• W4385655279 hasLocation W43856552792 @default.
• W4385655279 hasOpenAccess W4385655279 @default.
• W4385655279 hasPrimaryLocation W43856552791 @default.
• W4385655279 hasRelatedWork W1993687961 @default.
• W4385655279 hasRelatedWork W2051882359 @default.
• W4385655279 hasRelatedWork W2330456179 @default.
• W4385655279 hasRelatedWork W2435227317 @default.
• W4385655279 hasRelatedWork W2466043692 @default.
• W4385655279 hasRelatedWork W2611805711 @default.
• W4385655279 hasRelatedWork W2765980456 @default.
• W4385655279 hasRelatedWork W2976382042 @default.
• W4385655279 hasRelatedWork W3133599847 @default.
• W4385655279 hasRelatedWork W3206056578 @default.
• W4385655279 hasVolume "7" @default.
• W4385655279 isParatext "false" @default.
• W4385655279 isRetracted "false" @default.
• W4385655279 workType "article" @default.